How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

552 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Amenamevir, a novel helicase–primase inhibitor, for treatment of herpes zoster: A randomized, double‐blind, valaciclovir‐controlled phase 3 study (PubMed)

Amenamevir, a novel helicase–primase inhibitor, for treatment of herpes zoster: A randomized, double‐blind, valaciclovir‐controlled phase 3 study Amenamevir is a potent helicase-primase inhibitor and a novel class of antiviral agent other than nucleoside compounds, such as aciclovir, valaciclovir and famciclovir. This study is the first randomized, double-blind, valaciclovir-controlled phase 3 study to evaluate the efficacy and safety of amenamevir in Japanese patients with herpes zoster

Full Text available with Trip Pro

2017 The Journal of dermatology Controlled trial quality: predicted high

83. Treatment of Bell's Palsy - Should antivirals be added to prednisolone?

. Corticosterids vs corticosteroids plus antiviral agents in the treatment of Bell Palsy Arch Otolaryngol Head Neck Surg. 2009;135(6):558-564. Chen WL, Yang ZH, Huang ZQ. Outcome of treatment 46 patients with Bell's palsy with aciclovir and prednisone. [Chinese] Shanghai Kou Qiang Yi Xue/Shanghai Journal of Stomatology. 2005;14(6):590-2. Shahidullah M, Haque A, Islam MR, et al. Comparative Study between Combination of Famciclovir and Prednisolone with Prednisolone Alone in Acute Bell's Palsy. Mymensingh

2012 BestBETS

84. Retrospective cohort study: Does antiviral medication for treating herpes simplex during pregnancy increase the risk of birth defects in offspring?

? Article Text Aetiology Retrospective cohort study Does antiviral medication for treating herpes simplex during pregnancy increase the risk of birth defects in offspring? De-Kun Li Statistics from Commentary on: Pasternak B , Hviid A . Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects . Context The teratogenic effect of antiviral medication use during pregnancy has not been well evaluated in the human population. Among (...) the currently used antiviral medications, those used to treat herpes simplex such as acyclovir, valacyclovir and famciclovir are most common, although overall usage of antiviral medication in pregnant women remains low. Methods This was a data linkage study based on Danish national registries for both prescription drugs and birth defects registration data. Despite a study period covering close to 13 years of data with 837 795 births, only 1804 pregnant women used any of these three antiviral medications

2011 Evidence-Based Medicine (Requires free registration)

85. Antivirals for Preventing Post-Herpetic Neuralgia

many exclusion criteria, including immunocompromised state. Most trials used acyclovir, while one trial used famciclovir. The review fails to find a benefit to the acyclovir at 4 or 6 months, though interestingly at one month the analysis does suggest a benefit. The one trial that used famciclovir (at two different doses) also failed to show a benefit, with the Forrest plots in one case favoring placebo at a level that achives statistical significance. Harms were uncommon in both arms of all trials (...) and did not reach statistical significance. The Cochrane review concludes that acyclovir is not helpful in the prevention of PHN, but that larger trials with famciclovir may be useful, especially when looking at subgroups like age at time of zoster diagnosis or immunocompetence status. Caveats: Acyclovir has very well documented compliance issues, and this is no surprise when considering its recommended five-times-a-day dosing regimen. This may have led to compliance/adherence issues among patients

2011 theNNT

86. Surviving and fatal Elephant Endotheliotropic Herpesvirus-1A infections in juvenile Asian elephants – lessons learned and recommendations on anti-herpesviral therapy (PubMed)

Surviving and fatal Elephant Endotheliotropic Herpesvirus-1A infections in juvenile Asian elephants – lessons learned and recommendations on anti-herpesviral therapy Elephant Endotheliotropic Herpesviruses (EEHVs) can cause acute haemorrhagic disease in young Asian elephants (Elephas maximus) and clinical EEHV infections account for the majority of their fatalities. The anti-herpesviral drug famciclovir (FCV) has been used routinely to treat viraemic at-risk elephants, but thus far without

Full Text available with Trip Pro

2016 BMC veterinary research

87. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases (PubMed)

better than those reported in the studies that tested acyclovir, valacyclovir, and famciclovir. The current paper reports the effect of suppressive treatment with Gene-Eden-VIR/Novirin on the duration of outbreaks, in severe and mild genital herpes cases.The framework was a retrospective chart review. The population included 137 participants. The treatment was 1-4 capsules per day. The duration of treatment was 2-48 months. The study included three controls: baseline, no-treatment, and dose

Full Text available with Trip Pro

2016 Clinical and translational medicine

88. A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional

of immunoglobulins and/or any blood products within 3 months prior to Visit Month 0 of study ZOSTER-049 or planned administration during the study period. Prolonged use (> 14 consecutive days) of oral and/or parenteral antiviral agents that are active against VZV (acyclovir, valacyclovir, famciclovir, etc. ) and planned to be used during the study period for an indication other than to treat suspected or confirmed HZ or an HZ-related complication (topical use of these antiviral agents is allowed). Important

2016 Clinical Trials

89. Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity

mg/kg (TBW for normal weight patients and ABW40 for obese patients) as part of their routine care Weight > 190% of ideal body weight (IBW) for "obese" patients or weight 80-120% of IBW for matched control patients. Exclusion Criteria: Receipt of acyclovir or a pro-drug of acyclovir (valacyclovir, ganciclovir, valganciclovir, famciclovir) in the prior 24 hours Serum creatinine >1.5 mg/dL Hypersensitivity to acyclovir Patients requiring ventilator support or vasopressors in the prior 24 hours

2016 Clinical Trials

90. Efficacy and Safety of Nucleoside Antiviral Drugs for Treatment of Recurrent Herpes Labialis: A Systematic Review and Meta-Analysis. (PubMed)

of pain than did aciclovir. Both nucleoside antiviral drugs increased the percentage of aborted lesions, whereas penciclovir and famciclovir did not.Nucleoside antiviral drugs are safe and beneficial for the treatment of recurrent herpes labialis; both systemic and topical formulations are recommended. Valaciclovir is more effective than aciclovir, especially in reducing the time to healing of lesions.© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

2016 Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology

91. Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN). (PubMed)

at the first, third, and sixth months after rash outbreak in 3 groups: the acute group of patients who received LLLT during the first 5 days; the subacute group of patients who received LLLT during days 6 to 14 of the eruption; and the control group of patients who did not receive LLLT.There were 48, 48, and 154 patients in the acute, subacute, and control groups, respectively. After adjusting for confounding factors, including age, sex, and use of famciclovir, the incidence of PHN was significantly lower

2016 Journal of American Academy of Dermatology

92. WITHDRAWN: Antiviral treatment for Bell's palsy (idiopathic facial paralysis).

Fergus F Somasundara Dhruvashree D Sullivan Michael M Gammie Fiona F Sullivan Frank F eng Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review Systematic Review 2015 09 07 England Cochrane Database Syst Rev 100909747 1361-6137 0 Anti-Inflammatory Agents 0 Antiviral Agents 452-06-2 2-Aminopurine 9PHQ9Y1OLM Prednisolone HG18B9YRS7 Valine MZ1IW7Q79D Valacyclovir QIC03ANI02 Famciclovir X4HES1O11F Acyclovir IM Cochrane Database Syst Rev. 2015;(7):CD001869 26130372 2-Aminopurine analogs (...) & derivatives therapeutic use Acyclovir analogs & derivatives therapeutic use Anti-Inflammatory Agents therapeutic use Antiviral Agents therapeutic use Bell Palsy drug therapy virology Drug Therapy, Combination methods Famciclovir Herpes Simplex complications drug therapy Humans Prednisolone therapeutic use Randomized Controlled Trials as Topic Treatment Outcome Valacyclovir Valine analogs & derivatives therapeutic use 2015 9 8 6 0 2015 9 8 6 0 2016 4 1 6 0 epublish 26343420 10.1002/14651858.CD001869.pub7

Full Text available with Trip Pro

2016 The Cochrane database of systematic reviews

93. Blocking virus replication during acute MCMV infection paradoxically prolongs antigen presentation and increases the CD8+ T cell response by preventing type I IFN-dependent depletion of DCs (PubMed)

Blocking virus replication during acute MCMV infection paradoxically prolongs antigen presentation and increases the CD8+ T cell response by preventing type I IFN-dependent depletion of DCs Increasing amounts of pathogen replication usually lead to a proportionate increase in size and effector differentiation of the CD8+ T cell response, which is attributed to increased Ag and inflammation. Using a murine CMV that is highly sensitive to the antiviral drug famciclovir to modulate virus

Full Text available with Trip Pro

2016 Journal of immunology (Baltimore, Md. : 1950)

94. The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study (PubMed)

records were examined, and International Classification of Diseases, Ninth Revision, Clinical Modification and International Classification of Diseases, Tenth Revision, Clinical Modification codes were used to identify episodes of HZ between April 1, 1997 and March 31, 2014 in persons aged 20 or over. Annual age-adjusted incidence and hospitalization rates were calculated. Prescription records of HZ-diagnosed persons for acyclovir, valacyclovir, and famciclovir were used to calculate the rates

Full Text available with Trip Pro

2016 ClinicoEconomics and Outcomes Research: CEOR

95. Intérêt de la thérapie antivirale par voie orale dans le traitement des nécroses rétiniennes aigues (PubMed)

acuity. After the discovery of this disease using polymerase chain reaction (PCR) and immune load coefficient (ILC) usually by puncturing the cornea to evacuate the aqueous humour, the confirmation of this diagnosis allows for faster optimization of disease management decreasing the time required to confirm the diagnosis. ARN syndrome is associated with a very poor prognosis. Recent studies have shown that oral antiviral (valaciclovir, famciclovir and valganciclovir) and intravitreal therapies (...) as early as possible in order to limit bilateralization and the occurrence of complications. This study confirms that oral antiviral (valacyclovir, famciclovir and valganciclovir) and intravitreal therapies without initial intravenous treatment are an effective treatment for RNA.

Full Text available with Trip Pro

2016 The Pan African medical journal

96. Management of STIs and related conditions in children and young people

– consider if all other treatment modalities failed Genital Herpes First episode Treat if within 5 days of start of episode or while new lesions are still developing. Child 1 month–2 years Aciclovir 100 mg orally five times a day for 5 days Child >2 years Aciclovir 200 mg orally five times a day for 5 days Recurrence If episodic or suppressive therapy is required see adult guideline. NB: Valaciclovir and famciclovir are not licensed for use in children. 45 Anogenital candidiasis Child 12 years Treatment

2010 British Association for Sexual Health and HIV

97. Immune Response to Shingles Vaccination

chickenpox or shingles in the past 5 years. VZV seronegative Taking systemic suppressive regular doses of drugs with anti-VZV activity such as acyclovir, famciclovir, or valacyclovir. Episodic use is allowed. For Cohort 1: medication cannot be taken 24 hours prior to or 30 days after receiving Zostavax per CDC recommendations. HIV seropositive. Hepatitis C infection or active Hepatitis B infection. History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction) to gelatin, neomycin

2015 Clinical Trials

98. Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

glucocorticoid use is prohibited for Phase Ia patients) Any known contraindication to Zostavax® vaccine, including allergy or sensitivity to gelatin or any other vaccine component Known HIV/AIDS Currently receiving radiation or chemotherapy for any type of malignancy Any current use (within the last 30 days) of acyclovir, valacyclovir, famciclovir, or foscarnet Receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non

2015 Clinical Trials

99. HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

involvement which would require ventricular, cerebellar or brainstem inoculation or would require access through a ventricle in order to deliver treatment Prior participant in experimental viral therapy (e.g., adenovirus, retrovirus or herpes virus protocol) Required steroid increase within 1 week prior to injection Known HIV seropositivity Concurrent therapy with any drug active against HSV (acyclovir, valaciclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive

2015 Clinical Trials

100. Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

active against herpes viruses within 30 days prior to Day 1 including but not limited to: acyclovir, valacyclovir, famciclovir, penciclovir, ganciclovir and valganciclovir; 22.Use of any medication on a chronic basis; 23.Use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages within 72 hours prior to Check-in (Day -1); 24. Are taking or have utilized any drugs within 3 days prior to Day 1; alcohol or tobacco within 3 days prior to Day 1; or are a chronic alcohol

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>